1.World Health Organisation, Dementia. Fact sheet N°362. May 2017
2.Sims R, van der Lee SJ, Naj AC, Bellenguez C, Badarinarayan N, Jakobsdottir J, et al. Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer’s disease. Nature Genetics. 2017;49(9):1373–84.
3.Jevtic S, Sengar AS, Salter MW, McLaurin J, Zhang B, Gaiteri C, et al. The role of the immune system in Alzheimer disease: Etiology and treatment Integrated Systems Approach Identifies Genetic Nodes and Networks in Late-Onset Alzheimer’s Disease. Ageing Research Reviews. 2017;40(3):84–94.
4.Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, et al. TREM2 variants in Alzheimer’s disease. N Engl J Med. 2013;368.
5.Jonsson T, Stefansson H, Ph D SS, Jonsdottir I, Jonsson P, Snaedal J, et al. Variant of TREM2 Associated with the Risk of Alzheimer’s Disease. The New England journal of medicine. 2012;368(2):117–27.
6.Rosenthal SL, Bamne MN, Wang X, Berman S, Snitz BE, Klunk WE, et al. More evidence for association of a rare TREM2 mutation (R47H) with Alzheimer’s disease risk.
Neurobiol Aging. 2015 Aug;36(8):2443
7.Lambert J-CC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C, et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer’s disease. Nature Genetics. 2013;45(12):1452–8.
8.Filipello F, Morini R, Corradini I, Zerbi V, Canzi A, Michalski B, et al. The Microglial Innate Immune Receptor TREM2 Is Required for Synapse Elimination and Normal Brain Connectivity Fluctuation of the solvent‐accessible surface area of tuna ferrocytochrome c. Immunity. 2018;48(5):979–91
9.Allcock RJ, Barrow Ad Fau - Forbes S, Forbes S Fau - Beck S, Beck S Fau - Trowsdale J, Trowsdale J. The human TREM gene cluster at 6p21.1 encodes both activating and inhibitory single IgV domain receptors and includes NKp44. Eur J Immunol. 2003 Feb;33(2):567–77.
10.Kober DL, Wanhainen KM, Johnson BM, Randolph DT, Holtzman MJ, Brett TJ, et al. Preparation, crystallization, and preliminary crystallographic analysis of wild-type and mutant human TREM–2 ectodomains linked to neurodegenerative and inflammatory diseases
TREM2 mutations are rare in a French cohort of patients with frontotemporal dementia. Protein Expression and Purification. 2014;96(10):32–8.
11.Kober DL, Alexander-Brett JM, Karch CM, Cruchaga C, Colonna M, Holtzman MJ, et al. Neurodegenerative disease mutations in TREM2 reveal a functional surface and distinct loss-of-function mechanisms. Elife. 2016;5.
12.Zhao Y, Wu X, Li X, Jiang LL, Gui X, Liu Y, et al. TREM2 Is a Receptor for beta-Amyloid that Mediates Microglial Function. Neuron. 2018;97(5):1023–31
13.Yeh FL, Wang Y, Tom I, Gonzalez LC, Sheng M. TREM2 binds to apolipoproteins, including APOE and CLU/APOJ, and thereby facilitates uptake of amyloid-beta by microglia. Neuron. 2016;91.
14.Jendresen C, Årskog V, Daws MR, Nilsson LNG. The Alzheimer’s disease risk factors apolipoprotein E and TREM2 are linked in a receptor signaling pathway. Journal of Neuroinflammation. 2017;14(1)59
15.Atagi Y, Liu CC, Painter MM, Chen XF, Verbeeck C, Zheng H, et al. Apolipoprotein E is a ligand for triggering receptor expressed on myeloid cells 2 (TREM2). J Biol Chem. 2015;290.
16.Venselaar H, Te Beek TAH, Kuipers RKP, Hekkelman ML, Vriend G. Protein structure analysis of mutations causing inheritable diseases. An e-Science approach with life scientist friendly interfaces. BMC bioinformatics. 2010;11(1):548.
17.Vaser R, Adusumalli S, Leng SN, Sikic M, Ng PC. SIFT missense predictions for genomes. Nature Protocols. 2016;11(1):1–9.
18.Capriotti E, Fariselli P, Casadio R. I-Mutant2.0: Predicting stability changes upon mutation from the protein sequence or structure. Nucleic Acids Research. 2005;33
19.Gattis JL, Washington AV, Chisholm MM, Quigley L, Szyk A, McVicar DW, et al. The structure of the extracellular domain of triggering receptor expressed on myeloid cells like transcript–1 and evidence for a naturally occurring soluble fragment. J Biol Chem. 2006;281(19):13396–403.
20.Radaev S, Kattah M, Rostro B, Colonna M, Sun PD. Crystal structure of the human myeloid cell activating receptor TREM–1. Structure. 2003;11(12):1527–35.
21.Abduljaleel Z, Al-Allaf FA, Khan W, Athar M, Shahzad N, Taher MM, et al. Evidence of Trem2 variant associated with triple risk of alzheimer’s disease. PLoS ONE. 2014;9(3).
22.Zhong L, Wang Z, Wang D, Wang Z, Martens YA, Wu L, et al. Amyloid-beta modulates microglial responses by binding to the triggering receptor expressed on myeloid cells 2 (TREM2). Molecular neurodegeneration. 2018;13(1):15.
23.Zheng C, Wong CF, McCammon JA. Fluctuation of the solvent-accessible surface area of tuna ferrocytochrome c. Biopolymers. 1990;29(14):1877–83.
24.Sudom A, Talreja S, Danao J, Bragg E, Kegel R, Min X, et al. Molecular basis for the loss-of-function effects of the Alzheimer’s disease–associated R47H variant of the immune receptor TREM2 Critical aggregation concentration for the formation of early Amyloid-β (1–42) oligomers. Journal of Biological Chemistry. 2018;8(1).
25.Park JS, Ji IJ, Kim DH, An HJ, Yoon SY. The Alzheimer’s disease-associated R47H variant of TREM2 has an altered glycosylation pattern and protein stability. Frontiers in Neuroscience. 2017;10:1–10.
26.Pronk S, P ll Sr, Schulz R, Larsson P, Bjelkmar Pr, Apostolov R, et al. GROMACS 4.5: A high-throughput and highly parallel open source molecular simulation toolkit. Bioinformatics. 2013;29(7):845–54.
27.D. A. Case T. E. Cheatham II. AMBER 11. University of California, San Francisco; 2010.
28.Bava KA. ProTherm, version 4.0: thermodynamic database for proteins and mutants. Nucleic Acids Research. 2004;32